MARKET INSIGHTS

Global Infectious Diseases Preliminary Screening Tests market was valued at USD 1.45 billion in 2024. The market is projected to grow from USD 1.62 billion in 2025 to USD 2.95 billion by 2031, exhibiting a CAGR of 10.9% during the forecast period.

Infectious diseases preliminary screening tests are rapid diagnostic tools used to detect pathogens or biomarkers associated with diseases such as HIV, hepatitis, influenza, and malaria. These tests provide quick results, often within minutes, using samples like blood, saliva, or nasal swabs. Common formats include lateral flow assays, PCR-based tests, and immunoassays, which are widely used in clinics, laboratories, and home-testing settings.

The market growth is driven by increasing disease prevalence, rising demand for point-of-care testing, and advancements in diagnostic technologies. The COVID-19 pandemic significantly accelerated adoption, with companies like Abbott and Roche launching rapid antigen tests. However, regulatory challenges and accuracy limitations for some test types may restrain growth. North America dominates the market due to high healthcare expenditure, while Asia-Pacific shows the fastest growth due to improving healthcare infrastructure.

MARKET DYNAMICS

MARKET DRIVERS

Global Rise in Infectious Disease Prevalence Accelerates Market Demand

The infectious disease screening market is experiencing unprecedented growth due to the increasing global burden of communicable diseases. Recent data indicates over 17 million deaths annually worldwide are attributed to infectious diseases, with emerging pathogens accounting for approximately 20% of these cases. The COVID-19 pandemic demonstrated the critical need for rapid preliminary screening, with over 1 billion tests administered globally in 2023 alone. This has created sustained demand for cost-effective, rapid diagnostic solutions that can be deployed at scale. Governments worldwide are now prioritizing early detection systems, with screening test procurement budgets increasing by an average of 35% across developed nations since 2020.

Technological Advancements in Point-of-Care Testing Drive Market Expansion

Innovations in lateral flow assays and microfluidic technologies have revolutionized preliminary screening capabilities. Modern tests now deliver laboratory-comparable accuracy in under 15 minutes, with some HIV and malaria tests achieving sensitivity rates exceeding 98%. The point-of-care testing segment is projected to grow at 12.7% CAGR through 2031, fueled by the development of multiplex assays capable of detecting multiple pathogens simultaneously. Recent product launches include integrated smartphone-based readers that provide quantitative results without specialized equipment, significantly expanding testing accessibility in low-resource settings.

The global health security agenda has prioritized screening test availability, with 68 countries now mandating infectious disease testing protocols for high-risk populations and travel screenings.

Furthermore, the integration of artificial intelligence for test interpretation and blockchain for result verification is creating new standards in screening reliability. These technological synergies are reducing false-positive rates while improving epidemiological tracking capabilities across borders.

MARKET RESTRAINTS

Regulatory Complexity and Approval Delays Constrain Market Growth

While demand surges, the infectious disease screening market faces significant regulatory hurdles. The average approval timeline for new screening tests ranges from 12-18 months in major markets, with some multiplex assays requiring over 24 months for full certification. This creates bottlenecks in responding to emerging pathogens, as seen during recent outbreaks where test availability lagged 3-6 months behind viral emergence. Regulatory requirements vary substantially by region, with the EU's IVDR classification system adding additional compliance burdens that can increase development costs by 30-40%.

Other Restraints

Test Accuracy Concerns
Despite technological improvements, rapid tests continue to face scrutiny over variable performance. Studies show sensitivity rates for some influenza tests drop below 60% during early infection stages, while specificity issues plague certain tropical disease assays. These limitations necessitate confirmatory testing in up to 20% of cases, undermining the value proposition of preliminary screening solutions.

Reimbursement Challenges
Payer policies frequently lag behind technological advancements, with many healthcare systems refusing coverage for innovative screening modalities. In developing markets, out-of-pocket costs remain prohibitive, with rapid HIV tests costing patients 3-5 days' wages in some regions. This economic barrier significantly limits market penetration in high-prevalence, low-income areas.

MARKET OPPORTUNITIES

Emerging Markets Present Untapped Growth Potential

The Asia-Pacific region represents the fastest-growing market for infectious disease screening, with projected CAGR of 14.2% through 2031. Government initiatives like India's Ayushman Bharat program and China's tiered diagnosis system are driving massive testing infrastructure investments. Africa's diagnostic market, while currently underpenetrated, is poised for transformation with mobile health units and drone-delivered tests expanding access to remote populations. These developing regions account for over 80% of global infectious disease burden but currently represent less than 30% of screening test utilization.

Integration with Digital Health Ecosystems Creates New Value Chains

The convergence of diagnostic testing with digital health platforms is unlocking novel business models. Cloud-connected test devices now enable real-time disease surveillance, with data analytics identifying outbreak patterns 2-3 weeks before traditional reporting systems. Pharmaceutical companies are increasingly partnering with diagnostic firms, using screening data to optimize clinical trial site selection and patient recruitment. This integration is creating premium-priced, value-added services that command 40-60% higher margins than standalone test products.

Furthermore, employer-sponsored screening programs are expanding beyond occupational health mandates, with 42% of Fortune 500 companies now offering comprehensive infectious disease testing as part of employee wellness initiatives. This corporate health segment is projected to grow at 18% annually through the decade.

MARKET CHALLENGES

Supply Chain Vulnerabilities Threaten Market Stability

The infectious disease screening market remains highly susceptible to global supply chain disruptions. Critical test components including nitrocellulose membranes and colloidal gold conjugates face recurring shortages, with lead times extending from 4 to 26 weeks post-pandemic. Single-source dependencies for key raw materials create production bottlenecks, as evidenced when a 2023 factory fire reduced global lateral flow test output by 15% for six months. These vulnerabilities are compounded by increasing trade restrictions, with 37 countries currently imposing export controls on diagnostic components.

Other Challenges

Workforce Shortages
The global shortage of laboratory technicians and quality control specialists is impacting test manufacturing capacity. In the U.S. alone, clinical laboratory vacancies reached 12% in 2023, forcing manufacturers to delay product releases. Training pipelines cannot keep pace with industry growth, with educational programs producing only 60% of required graduates annually.

Data Privacy Concerns
Expanded digital integration raises significant data security issues, particularly for tests involving genetic analysis. Recent surveys indicate 68% of consumers hesitate to use connected health devices due to privacy concerns. Evolving data protection regulations across jurisdictions create compliance risks, with potential fines reaching 4% of global revenue for violations.

Infectious Diseases Preliminary Screening Tests Market

The global Infectious Diseases Preliminary Screening Tests market was valued at $1,450 million in 2024 and is projected to reach $2,949 million by 2031, growing at a compound annual growth rate (CAGR) of 10.9% during the forecast period. These tests encompass rapid diagnostic tools, such as breath, saliva, or other point-of-care assays, designed for initial detection of infectious agents to guide further medical decisions. As emerging viruses and infectious diseases continue to pose significant public health threats, the demand for quick, accessible screening has surged. Key growth drivers include the advantages of rapid testing over traditional laboratory methods, supportive government and private sector initiatives to bolster healthcare infrastructure, rising global health expenditures, and favorable policies promoting early detection and outbreak response.

Industry stakeholders, including manufacturers, suppliers, and distributors, highlight increasing sales and revenue driven by heightened demand, fluctuating prices influenced by supply chain dynamics, and ongoing product innovations. Recent developments focus on enhancing test accuracy and portability, while challenges such as regulatory hurdles and potential supply shortages present risks. This analysis provides quantitative and qualitative insights to support strategic business decisions in this evolving landscape.

Segment Analysis:

By Type

Professional Rapid Test Product Segment Dominates the Market Due to its Reliability in Clinical and Diagnostic Settings

The market is segmented based on type into:

• Over-the-Counter Rapid Test Product

• Professional Rapid Test Product

Professional rapid test products hold a leading position owing to their widespread use in healthcare facilities where precision and integration with laboratory workflows are critical for confirming preliminary results. These tests enable healthcare professionals to conduct on-site screenings for infectious diseases, reducing turnaround times and facilitating prompt patient management. In contrast, over-the-counter options are gaining traction for home-based testing, particularly in response to pandemics, though they face limitations in sensitivity compared to professional-grade assays. The shift toward decentralized diagnostics underscores the growth potential in both segments, with professional products benefiting from higher adoption rates in hospital and clinic environments.

By Application

HIV and Hepatitis Segments Lead Due to High Global Prevalence and Targeted Screening Programs

The market is segmented based on application into:

• Infectious Diseases

• Hepatitis

• Influenza

• Malaria

• HIV

• Other

Applications targeting HIV and hepatitis dominate due to the persistent global burden of these conditions and the emphasis on widespread screening initiatives by health organizations. Influenza screening has seen accelerated growth post-pandemic, driven by seasonal outbreaks and the need for rapid community surveillance. Malaria applications are particularly vital in endemic regions, where point-of-care tests support immediate treatment decisions in resource-limited settings. The broader infectious diseases category encompasses emerging pathogens, while the 'other' segment includes tests for tuberculosis and tropical diseases. Overall, these applications reflect a market responsive to epidemiological priorities, with innovations aimed at multiplex testing to cover multiple diseases simultaneously.

Key Players

The competitive landscape features prominent companies driving innovation and market expansion through product launches, partnerships, and regulatory approvals. Leading participants include:

• Abbott

• BD

• Bio-Rad Laboratories, Inc.

• Cepheid

• Hologic Inc.

• Meridian Bioscience, Inc.

• OraSure Technologies, Inc.

• Quidel Corporation

• F. Hoffmann-La Roche Ltd.

• Bureau Veritas

• Eurofins Scientific

• Siemens Healthcare Private Limited

• Luminex Corporation

• PerkinElmer Inc.

• QIAGEN

• Mesa Biotech

• Illumina, Inc.

These firms collectively command significant market share, with strategies focused on expanding portfolios for rapid, user-friendly screening solutions amid rising infectious disease threats.

COMPETITIVE LANDSCAPE

Key Industry Players

Companies Strive to Strengthen their Product Portfolio to Sustain Competition

The competitive landscape of the Infectious Diseases Preliminary Screening Tests market remains semi-consolidated, featuring a mix of large, medium, and small-sized players that drive innovation and market expansion. Abbott stands out as a leading force in this space, thanks to its robust lineup of rapid diagnostic solutions and extensive global footprint spanning North America, Europe, Asia-Pacific, and beyond. The company's focus on point-of-care testing kits for diseases like HIV and influenza has solidified its position, enabling quick preliminary screenings that are crucial in high-prevalence areas.

BD and Bio-Rad Laboratories, Inc. also commanded a substantial market share in 2024, with their growth fueled by cutting-edge technologies in lateral flow assays and molecular diagnostics tailored for infectious disease detection. These firms benefit from strong ties to healthcare providers and research institutions, which bolster demand for their over-the-counter and professional rapid test products. For instance, BD's advancements in sample collection devices have enhanced the accuracy and speed of preliminary screenings, addressing the rising need for accessible testing amid emerging viral threats.

Furthermore, ongoing growth strategies among these players, including strategic acquisitions, geographic expansions into emerging markets, and frequent new product launches, are poised to amplify their market shares through the forecast period ending in 2031. As the global market, valued at US$ 1,450 million in 2024, projects to reach US$ 2,949 million by 2031 at a CAGR of 10.9%, such initiatives respond directly to increasing infectious disease burdens and supportive government policies promoting rapid diagnostics.

Meanwhile, F. Hoffmann-La Roche Ltd and Quidel Corporation are intensifying their foothold through hefty R&D investments, collaborative partnerships with health organizations, and expansions in multiplex testing platforms. These efforts not only counter challenges like supply chain disruptions but also ensure sustained competitiveness by delivering reliable, user-friendly screening tests for applications ranging from hepatitis to malaria. However, smaller players face hurdles in scaling production, yet the overall landscape encourages innovation to meet evolving regulatory standards and consumer needs for faster, more affordable preliminary assessments.

List of Key Infectious Diseases Preliminary Screening Tests Companies Profiled

• Abbott (U.S.)

• BD (U.S.)

• Bio-Rad Laboratories, Inc. (U.S.)

• Cepheid (U.S.)

• Hologic Inc. (U.S.)

• Meridian Bioscience, Inc. (U.S.)

• OraSure Technologies, Inc. (U.S.)

• Quidel Corporation (U.S.)

• F. Hoffmann-La Roche Ltd (Switzerland)

• BUREAU VERITAS (France)

• Eurofins Scientific (Luxembourg)

• Siemens Healthcare Private Limited (Germany)

• Luminex Corporation (U.S.)

• PerkinElmer Inc. (U.S.)

• QIAGEN (Germany)

• Mesa Biotech (U.S.)

• Illumina, Inc. (U.S.)

Infectious Diseases Preliminary Screening Tests Market Trends

Rise of Point-of-Care Testing Innovations to Drive Market Expansion

The global Infectious Diseases Preliminary Screening Tests market, valued at US$ 1,450 million in 2024, is projected to reach US$ 2,949 million by 2031, growing at a compound annual growth rate (CAGR) of 10.9% during the forecast period. This robust expansion is largely fueled by advancements in point-of-care (POC) testing technologies, which enable rapid, on-site detection of infectious agents without the need for centralized laboratories. Innovations such as lateral flow assays and nucleic acid amplification tests have transformed preliminary screening, allowing healthcare professionals to obtain results in minutes rather than days. For instance, the development of multiplex platforms that can simultaneously screen for multiple pathogens, including viruses and bacteria, has become crucial in managing outbreaks. While traditional lab-based methods remain accurate, the shift toward portable, user-friendly devices addresses the growing need for immediate screening in remote or resource-limited settings. Furthermore, the integration of digital connectivity in these tests linking results directly to electronic health records enhances data management and supports real-time epidemiological surveillance. However, challenges like ensuring test sensitivity and specificity persist, prompting ongoing research to refine these tools. As global health threats evolve, such as with emerging variants of influenza or hepatitis, the demand for these innovative screening solutions continues to surge, positioning POC testing as a cornerstone trend in the market.

Other Trends

Increased Adoption of Over-the-Counter Rapid Tests

The rising popularity of over-the-counter (OTC) rapid test products represents a significant shift in how individuals approach infectious disease screening, empowering consumers to detect conditions like HIV, malaria, or influenza at home. This trend is particularly evident in segments where accessibility trumps the need for professional oversight, with OTC tests accounting for a substantial portion of the market's growth. By 2024, these products held a notable share in the type segment, driven by user-friendly designs and quick turnaround times that reduce barriers to early detection. While professional rapid tests dominate in clinical environments, the convenience of OTC options has accelerated their penetration in both developed and developing regions. This democratization of testing not only alleviates pressure on healthcare systems but also promotes proactive health management. Yet, concerns over result interpretation and false positives highlight the need for educational campaigns alongside product improvements. Overall, this trend underscores a broader movement toward self-reliant healthcare, fostering market diversification and innovation in consumer-facing diagnostics.

Government and Private Sector Initiatives Boosting Surveillance Efforts

Government policies and private investments are playing a pivotal role in amplifying the use of preliminary screening tests, especially in response to rising infectious disease prevalence worldwide. Initiatives aimed at expanding healthcare infrastructure, coupled with increased global health spending, have created fertile ground for market growth. For example, programs targeting high-burden diseases like hepatitis and HIV have led to widespread distribution of affordable screening kits in low-income areas. These efforts not only enhance early intervention but also contribute to curbing transmission rates through population-level monitoring. In parallel, private sector collaborations with biotech firms are accelerating the development of next-generation tests, focusing on scalability and cost-effectiveness. However, regulatory hurdles and supply chain disruptions can impede progress, necessitating adaptive strategies from stakeholders. This synergy between public and private domains is essential, as it addresses the multifaceted challenges of infectious disease control while propelling the market toward sustainable expansion.

Expansion in Emerging Markets and Application Diversification

The broadening of the Infectious Diseases Preliminary Screening Tests market into emerging economies, particularly in Asia and Africa, is a key driver reshaping industry dynamics. Regions like Southeast Asia and sub-Saharan Africa, where diseases such as malaria and tuberculosis remain endemic, are witnessing heightened investment in screening infrastructure, leading to a projected increase in market share for these areas by 2031. This expansion is supported by favorable policies that prioritize rapid diagnostics to bolster public health systems, alongside rising awareness of preventive screening. In terms of applications, the market is diversifying beyond general infectious diseases to specialized segments like influenza and HIV, with these categories expected to capture growing revenues due to seasonal outbreaks and ongoing global campaigns. New product launches from leading players, including portable multiplex assays, are further catalyzing adoption across diverse settings from hospitals to community health centers. Collaborative research initiatives between international organizations and local manufacturers are also uncovering novel biomarkers, enhancing test accuracy for region-specific pathogens. While economic disparities pose challenges, the overall trajectory points to inclusive growth, with the application segments for hepatitis and other tropical diseases gaining momentum through targeted interventions. This multifaceted expansion not only mitigates health risks but also opens avenues for sustained market penetration and innovation.

Regional Analysis: Infectious Diseases Preliminary Screening Tests Market

North America
North America leads the global Infectious Diseases Preliminary Screening Tests market, driven by advanced healthcare infrastructure and a strong emphasis on rapid diagnostic solutions. The region's market benefits from high awareness levels and proactive public health measures, particularly following the COVID-19 pandemic, which accelerated the adoption of over-the-counter and professional rapid test products. In the United States, the Food and Drug Administration (FDA) has played a pivotal role in approving innovative screening tests for diseases like HIV, influenza, and hepatitis, ensuring safety and efficacy. This regulatory framework supports market growth while maintaining high standards. Furthermore, substantial investments in healthcare research and development, including initiatives by the Centers for Disease Control and Prevention (CDC), have bolstered demand for preliminary screening tools that enable quick triage in clinical and community settings. The shift toward point-of-care testing is evident, as healthcare providers seek to reduce turnaround times compared to traditional laboratory methods. However, challenges such as reimbursement policies and the need for continuous validation of test accuracy persist. Canada's robust universal healthcare system further contributes to market expansion, with provinces investing in screening programs for infectious diseases prevalent in indigenous communities and urban centers. Mexico, while facing economic constraints, is seeing gradual uptake through partnerships with international manufacturers like Abbott and Roche, focusing on affordable tests for malaria and dengue in border regions. Overall, North America's market is projected to grow steadily, fueled by rising incidences of respiratory infections and sexually transmitted diseases, alongside technological advancements in multiplex testing that detect multiple pathogens simultaneously. The focus on integration with digital health platforms enhances usability, allowing real-time data sharing for outbreak management. While supply chain disruptions occasionally impact availability, the region's strong domestic manufacturing base, including key players like BD and Cepheid, ensures resilience. As global health threats evolve, North America remains at the forefront, prioritizing accessible and reliable preliminary screening to safeguard public health.

Europe
Europe's Infectious Diseases Preliminary Screening Tests market is characterized by stringent regulatory oversight and a commitment to harmonized health policies across member states, fostering a mature and innovative landscape. The European Medicines Agency (EMA) guidelines ensure that tests for influenza, HIV, and hepatitis meet rigorous performance criteria, promoting trust among healthcare professionals and consumers. Countries like Germany and France lead in adoption, with integrated public health systems emphasizing early detection to control disease spread. For instance, the European Centre for Disease Prevention and Control (ECDC) supports widespread screening initiatives, particularly for emerging viral threats, which has driven demand for professional rapid tests in hospitals and clinics. The United Kingdom, post-Brexit, continues to invest heavily in domestic production, as seen with companies like Roche and Siemens Healthcare advancing point-of-care diagnostics. However, varying reimbursement structures across nations pose challenges, with some southern European countries lagging due to economic pressures. Nordic countries, known for their efficient healthcare models, excel in over-the-counter test accessibility, targeting home-based screening for seasonal flu and other respiratory illnesses. Italy and Spain, having experienced significant outbreaks, have enhanced surveillance systems incorporating preliminary tests to inform policy decisions. Benelux nations focus on collaborative research, accelerating the development of next-generation tests with improved sensitivity. Russia and the rest of Eastern Europe present opportunities amid rising infectious disease burdens, though infrastructure gaps hinder full penetration. The region's emphasis on sustainability influences product design, favoring eco-friendly test kits. As novel pathogens emerge, Europe's collaborative approach through initiatives like the Horizon Europe program strengthens market dynamics, encouraging innovation while addressing disparities in access. Challenges include supply shortages during peaks, but overall, the market thrives on a balance of compliance, technological progress, and public health integration, positioning Europe as a key growth hub.

Asia-Pacific
Asia-Pacific represents the fastest-growing region in the Infectious Diseases Preliminary Screening Tests market, propelled by dense populations, urbanization, and heightened vulnerability to infectious outbreaks. China and India dominate, accounting for substantial market share due to extensive government-backed screening programs for diseases like tuberculosis, hepatitis, and malaria. In China, the National Health Commission has integrated rapid tests into primary care, enhancing early detection in rural and urban areas alike. India's initiatives, such as the Ayushman Bharat scheme, promote affordable over-the-counter products, addressing the high burden of vector-borne illnesses. Japan and South Korea, with their advanced biotech sectors, lead in professional rapid tests, incorporating AI for result interpretation to combat influenza and emerging coronaviruses. Southeast Asia, including Indonesia and Thailand, faces challenges from tropical diseases but benefits from international aid and local manufacturing by firms like QIAGEN. The region's cost sensitivity favors low-priced options, yet there's a noticeable shift toward high-accuracy professional tests in private hospitals. Economic growth enables increased health spending, supporting market expansion, while challenges like counterfeit products and uneven regulatory enforcement persist. Rest of Asia sees potential in countries like Australia, where stringent biosecurity measures drive demand for HIV and STI screening. Urbanization exacerbates disease transmission, necessitating portable, user-friendly tests for community health workers. Collaborations between global players like Abbott and local entities accelerate innovation, such as multiplex kits for multiple applications. As climate change influences disease patterns, Asia-Pacific's market evolves with a focus on scalability and equity, ensuring preliminary screening reaches underserved populations effectively.

South America
South America's Infectious Diseases Preliminary Screening Tests market is emerging, influenced by diverse healthcare landscapes and ongoing efforts to combat endemic diseases like dengue, Zika, and Chagas. Brazil, the largest economy, drives regional growth through its unified health system (SUS), which incorporates rapid tests for HIV and hepatitis in public clinics, supported by partnerships with international suppliers. Argentina focuses on influenza and malaria screening in northern provinces, where access to lab facilities is limited, making preliminary tests essential for timely interventions. However, economic instability and inflation challenge affordability, leading to reliance on donated or subsidized kits from organizations like the Pan American Health Organization (PAHO). Rest of South America, including Colombia and Peru, experiences sporadic outbreaks, prompting government investments in border surveillance using professional rapid products. The region's tropical climate heightens the need for robust, heat-stable tests, an area where companies like Bio-Rad and Meridian Bioscience are innovating. While urban centers in major cities boast advanced diagnostics, rural areas suffer from supply chain issues and low awareness, hindering widespread adoption. Favorable policies aim to integrate screening into national vaccination drives, but bureaucratic hurdles slow progress. As private sector involvement grows, particularly in telemedicine-linked testing, opportunities arise for over-the-counter options targeting self-testing. Challenges such as political unrest and funding shortages temper optimism, yet the market shows resilience through community-based programs. Long-term, improving infrastructure and international collaborations could unlock greater potential, emphasizing preventive health to mitigate economic impacts of epidemics.

Middle East & Africa
The Middle East and Africa region presents a nascent yet promising Infectious Diseases Preliminary Screening Tests market, shaped by varying levels of development and persistent health challenges. In the Middle East, countries like Saudi Arabia and the UAE leverage oil revenues to modernize healthcare, investing in rapid tests for HIV, hepatitis, and tuberculosis through initiatives like Saudi Vision 2030. Turkey and Israel advance with homegrown technologies, focusing on point-of-care solutions for pilgrims and migrant populations. However, geopolitical tensions disrupt supply chains, affecting availability. Africa, with its high disease burden from malaria, Ebola, and HIV, relies on international aid from bodies like the World Health Organization (WHO) to distribute affordable tests. South Africa leads the continent, integrating professional rapid products into its antiretroviral programs, while Nigeria and Kenya expand over-the-counter access in urban slums. Challenges include weak regulatory frameworks, counterfeit risks, and logistical barriers in remote areas, which limit penetration. Rest of the region, encompassing Egypt and Ethiopia, sees gradual uptake driven by mobile clinics and NGO efforts. Rising foreign direct investment in biotech hubs, such as in Rwanda, fosters local production. As urbanization accelerates, demand for quick screening rises to manage migrant health and outbreaks. Environmental factors like water scarcity exacerbate vector-borne diseases, underscoring the need for durable tests. While funding gaps and infrastructure deficits slow growth, policy reforms and public-private partnerships offer pathways to expansion. The market's trajectory hinges on capacity building, ensuring equitable access to preliminary screening tools that can transform outbreak responses and public health outcomes.

Infectious Diseases Preliminary Screening Tests Market

Report Scope

This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.

Key Coverage Areas:

• Market Overview

  • The global Infectious Diseases Preliminary Screening Tests market was valued at USD 1,450 million in 2024 and is projected to reach USD 2,949 million by 2031, growing at a compound annual growth rate (CAGR) of 10.9% during the forecast period. This growth reflects the increasing demand for rapid diagnostic solutions amid rising infectious disease prevalence worldwide. Historically, the market has seen steady expansion from USD 1,200 million in 2020, driven by advancements in point-of-care testing technologies. Regionally, North America holds the largest share at approximately 35% in 2024, while Asia-Pacific is expected to grow the fastest at a CAGR of 12.5% through 2031, fueled by expanding healthcare infrastructure in emerging economies.

  • Growth trends indicate a shift toward user-friendly, high-accuracy rapid tests, with volume projections estimating sales to rise from 150 million units in 2024 to over 350 million units by 2031. Value projections align with revenue forecasts, emphasizing the role of portable and cost-effective screening tools in combating outbreaks like COVID-19 and influenza. Key trends include integration of digital reporting for faster results dissemination, supporting global health surveillance efforts.

• Segmentation Analysis

  • By product type, the market is divided into Over-the-Counter Rapid Test Products and Professional Rapid Test Products. In 2024, Professional Rapid Test Products dominate with a 65% market share, valued at USD 942.5 million, due to their use in clinical settings for accurate preliminary screening. Over-the-Counter products, however, are growing rapidly at 13% CAGR, reaching USD 507.5 million, as consumers seek accessible home-testing options for early detection.

  • By application, segments include Infectious Diseases, Hepatitis, Influenza, Malaria, HIV, and Others. HIV screening leads with 25% share in 2024, followed by Influenza at 20%, driven by seasonal epidemics and public health campaigns. The Hepatitis segment is projected to grow at 11.5% CAGR, supported by vaccination drives and awareness programs in high-prevalence regions.

  • By end-user industry, primary segments are hospitals and clinics, diagnostic laboratories, and home care settings. Hospitals account for 50% of the market in 2024, with diagnostic labs growing due to outsourcing trends. Home care is an emerging segment, expected to double in size by 2031 as self-testing gains acceptance.

  • By distribution channel, direct sales to healthcare providers and retail pharmacies are key, with online platforms emerging post-pandemic, contributing 15% to distribution in 2024 and projected to reach 25% by 2031 for greater accessibility.

• Regional Insights

  • North America commands 35% of the global market in 2024, valued at USD 507.5 million, with strong regulatory support and advanced healthcare systems. Europe follows at 30%, driven by initiatives in the UK and Germany. Asia-Pacific, at 25%, is the fastest-growing due to population density and disease burden. Latin America and Middle East & Africa together hold 10%, with potential for expansion through international aid.

  • Country-level data highlights the US leading at USD 400 million in 2024, projected to reach USD 800 million by 2031. China in Asia-Pacific is valued at USD 200 million, growing at 14% CAGR. In Europe, Germany and France each contribute around USD 150 million, while India's market is expanding rapidly from USD 100 million in 2024.

• Competitive Landscape

  • Major players include Abbott, BD, Bio-Rad Laboratories, Inc., Cepheid, Hologic Inc., Meridian Bioscience, Inc., OraSure Technologies, Inc., Quidel Corporation, F. Hoffmann-La Roche Ltd, Bureau Veritas, Eurofins Scientific, Siemens Healthcare Private Limited, Luminex Corporation, PerkinElmer Inc., QIAGEN, Mesa Biotech, and Illumina, Inc. Abbott holds the largest market share at 15% in 2024, followed by Roche at 12%, based on revenue from rapid test kits.

  • Key strategies involve mergers and acquisitions, such as Abbott's acquisition of Alere in 2017 for enhanced diagnostics portfolio, and partnerships like BD with Bio-Rad for test development. Expansions focus on emerging markets, with QIAGEN investing in Asia-Pacific R&D facilities.

  • Product portfolios feature rapid antigen and antibody tests, with pricing strategies emphasizing affordability; for instance, over-the-counter kits priced at USD 5-10 per unit to penetrate consumer markets, while professional kits range from USD 20-50, balancing quality and accessibility.

• Technology & Innovation

  • Emerging technologies include lateral flow assays and molecular diagnostics for faster screening, with R&D trends focusing on multiplex tests detecting multiple pathogens simultaneously. Investments in nanotechnology enhance sensitivity, reducing false negatives in preliminary screenings.

  • Automation and digitalization are integrating with apps for result tracking, while sustainability initiatives promote eco-friendly test kits using biodegradable materials. These efforts align with global health goals for reduced waste in diagnostics.

  • The impact of AI involves predictive analytics for outbreak forecasting, and IoT enables connected devices for real-time data sharing in surveillance networks, revolutionizing preliminary screening efficiency in remote areas.

• Market Dynamics

  • Key drivers include the rising prevalence of infectious diseases, benefits of rapid testing over lab methods, government initiatives to bolster healthcare, and increasing global health spending, which reached USD 10 trillion in 2023. Favorable policies, such as WHO's push for accessible diagnostics, further accelerate growth.

  • Restraints encompass regulatory hurdles for test approvals and accuracy concerns leading to potential misdiagnoses. Risk factors involve supply shortages during pandemics and counterfeit products eroding trust in preliminary screenings.

  • Supply chain trends show localization to mitigate disruptions, with challenges like raw material volatility for reagents. Post-COVID, diversified sourcing has stabilized availability, though geopolitical tensions pose ongoing risks.

• Opportunities & Recommendations

  • High-growth segments include over-the-counter tests and HIV/influenza applications, expected to capture 40% of incremental growth by 2031 due to home-testing adoption.

  • Investment hotspots are Asia-Pacific and Latin America, where untapped markets offer 15%+ CAGR potential through infrastructure development and public-private partnerships.

  • Strategic suggestions for stakeholders involve R&D collaboration for innovative tests, market entry via local partnerships, and adoption of digital tools for supply chain optimization to capitalize on global health demands.

• Stakeholder Insights

  This report is designed to support strategic decision-making for a wide range of stakeholders, including:

  • Pharmaceutical and biotech companies

  • Medical device and diagnostics manufacturers

  • Healthcare providers and hospital systems

  • Contract research and manufacturing organizations

  • Investors, consultants, and policy makers

FREQUENTLY ASKED QUESTIONS:

What is the current market size of Global Infectious Diseases Preliminary Screening Tests Market?

-> The global Infectious Diseases Preliminary Screening Tests market was valued at USD 1,450 million in 2024 and is expected to reach USD 2,949 million by 2031.

Which key companies operate in Global Infectious Diseases Preliminary Screening Tests Market?

-> Key players include Abbott, BD, Bio-Rad Laboratories, Inc., Cepheid, Hologic Inc., Meridian Bioscience, Inc., OraSure Technologies, Inc., Quidel Corporation, and F. Hoffmann-La Roche Ltd, among others.

What are the key growth drivers?

-> Key growth drivers include emergence of novel viruses, increasing prevalence of infectious diseases, benefits of rapid testing, and government initiatives to expand healthcare sectors.

Which region dominates the market?

-> North America dominates the market, while Asia-Pacific is the fastest-growing region.

What are the emerging trends?

-> Emerging trends include multiplex rapid tests, point-of-care digital integration, and sustainable diagnostic solutions for global health monitoring.